P R O H O S T   O n l i n e The Newsletter of Biotechnology Insight and Investment
Eye on the News [ Home | Contents | Search | Next | Previous | Up ]

XOMA FINACES

milfnextdoor x nd24 x

Date: 12 Dec 2007
Time: 09:35:03

Comments

http://www.milfnextdoor.com/main.htm?id=chikenn http://www.milfpass.com/main.htm?id=chikenn http://www.moneytalks.com/main.htm?id=chikenn http://www.papi.com/main.htm?id=chikenn http://www.pure18.com/main.htm?id=chikenn http://www.realitykings.com/main.htm?id=chikenn http://www.milfhunter.com/?id=chikenn http://www.roundandbrown.com/main.htm?id=chikenn http://www.streetblowjobs.com/main.htm?id=chikenn

Date: 27 Jun 2001
Time: 14:22:56

Comments

XOMA Completes $43 Million Common Share Financing Berkeley, CA -- June 26, 2001 -- XOMA Ltd. (NASDAQ: XOMA) today announced it has agreed to sell three million common shares in an offering underwritten by U.S. Bancorp Piper Jaffray, CIBC World Markets, Adams, Harkness & Hill and Arnhold & S. Bleichroeder, Inc., subject to customary closing conditions, for net proceeds after expenses and fees of approximately $43.3 million.

"Our objective was to secure sufficient funding to meet our projected needs with a prudent reserve through our currently anticipated timeline for the commercialization of Xanelim," said Peter B. Davis, XOMA’s Vice President of Finance and CFO. "We were pleased that the demand for XOMA shares enabled us to meet that objective."

XOMA develops and manufactures antibody and other protein-derived biopharmaceuticals for disease targets that include cancer, immunological and inflammatory disorders and infectious diseases. For more information about XOMA's pipeline and activities, please visit XOMA's web site at www.xoma.com.

Statements made in this press release related to the sufficiency of the Company’s cash position, timing of clinical trials, the FDA regulatory process, collaborative relationships, other aspects of product development, or that otherwise relate to future periods, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. These risks, including those related to the timing or results of pending or future clinical trials, changes in the status of the Company’s collaborative relationships, uncertainties regarding the legal standards applicable to biotechnology patents, and actions by the U.S. Food and Drug Administration or the U.S. Patent and Trademark Office, are discussed in the Company’s most recent annual report on Form 10-K and in other SEC filings. Consider such risks carefully in evaluating XOMA’s prospects

Prohost is an independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Send mail to CompanyWebmaster with questions or comments about this web site. Copyright © 2001 CompanyLongName